Biotechnology Companies' Quarterly Results - Research Report on Geron, Santarus, Merrimack, Clovis, and Arena
NEW YORK, November 12, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Geron Corporation (NASDAQ: GERN), Santarus, Inc. (NASDAQ: SNTS), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Clovis Oncology, Inc. (NASDAQ: CLVS), and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Geron Corporation Research Report
On November 7, 2013, Geron Corporation (Geron) released its Q3 2013 results. Geron registered revenues of c.$0.2 million in Q3 2013, compared to revenues of c.$0.6 million in Q3 2012. The Company posted net loss of $8.3 million in Q3 2013, compared to net loss of $16.0 million in Q3 2012. Geron reported diluted loss per share of $0.06 in Q3 2013, compared to diluted loss per share of $0.13 in Q3 2012. The Full Research Report on Geron Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/1ca9_GERN]
Santarus, Inc. Research Report
On November 7, 2013, Santarus, Inc. (Santarus) released its Q3 2013 results. Santarus registered total revenues of $98.8 million in Q3 2013, up 80.7% YoY. The Company posted net income of $30.3 million in Q3 2013, up 237.5% YoY. Santarus reported diluted EPS of $0.38 in Q3 2013, up 192.3% YoY. The Full Research Report on Santarus, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/22f8_SNTS]
Merrimack Pharmaceuticals, Inc. Research Report
On November 7, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) released its Q3 2013 results. Merrimack registered collaboration revenues of $11.3 million in Q3 2013, up 65.2% YoY. The Company posted net loss attributable to Merrimack of $23.2 million in Q3 2013, compared to net loss attributable to Merrimack of $39.6 million in Q3 2012. Merrimack reported diluted loss per share of $0.25 in Q3 2013, compared to diluted loss per share of $0.39 in Q3 2012. The Company expects its existing unrestricted cash and cash equivalents and available-for-sale securities as of September 30, 2013 of $182.5 million, anticipated interest income and funding under its license and collaboration agreement with Sanofi related to MM-121 to be sufficient to fund operations into 2015. Merrimack informed that if it achieves favorable results from the MM-398 NAPOLI-1 trial, the Company expects anticipated additional expenses in 2014 related to the commercialization of MM-398 to be offset by cash received from potential collaboration opportunities. The Full Research Report on Merrimack Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/8bb0_MACK]
Clovis Oncology, Inc. Research Report
On October 31, 2013, Clovis Oncology, Inc. (Clovis) released its Q3 2013 results. Clovis registered net loss of $20.3 million in Q3 2013, compared to net loss of $18.3 million in Q3 2012. The Company posted diluted net loss per common share of $0.68 in Q3 2013, compared to diluted net loss per common share of $0.71 in Q3 2012. Commenting on the Company's clinical development programs, Patrick J. Mahaffy, President and CEO of Clovis, said, "We are very pleased by the data recently presented for both CO-1686 and rucaparib and the progress being made on both programs." Mahaffy continued, "Given the encouraging results we've seen for CO-1686 to date, we look forward to identifying the Phase 2 dose with our improved HBr formulation by the end of 2013, and then commencing our initial registration study in the first half of 2014. This will be our first pivotal trial of a broad and global clinical development plan for CO-1686." The Full Research Report on Clovis Oncology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/6a2a_CLVS]
Arena Pharmaceuticals, Inc. Research Report
On November 7, 2013, Arena Pharmaceuticals, Inc. (Arena) released its Q3 2013 results. Arena registered total revenues of $3.6 million in Q3 2013, up 140.9% YoY. The Company posted net loss allocable to common shareholders of $17.2 million in Q3 2013, compared to net loss allocable to common shareholders of $15.5 million in Q3 2012. Arena reported diluted loss per share of $0.08 in Q3 2013, compared to diluted loss per share of $0.07 in Q3 2012. Jack Lief, Arena's President and CEO, stated, "We are excited by our expanded agreement with Eisai and look forward to collaborating as we focus on the global registration and commercialization of BELVIQ for weight management and the development of potential new indications." Lief continued, "Our third quarter results reflect the first full quarter since BELVIQ became available in US pharmacies. Additional work is needed to continue building the weight management market, and we are pleased with Eisai's commitment to realizing the medical and commercial potential of BELVIQ. We look forward to the market growth of this important treatment option as we move into 2014." The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/6a95_ARNA]
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.AnalystsCorner.com/
SOURCE Analysts' Corner
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article